China\u2019s Innovent Biologics said on Monday its GLP-1 injection led to more weight loss and better control of blood sugar in patients with diabetes than injectable semaglutide, the active ingredient in Novo Nordisk\u2019s diabetes and weight-loss medicines.<\/p>\n
The late-stage head-to-head trial compared different doses of the two drugs in patients with diabetes and obesity to assess glycemic control and weight loss. One group received a 6 mg dose of the mazdutide drug that Innovent develops and the other a 1 mg dose of injectable semaglutide.<\/p>\n
Innovent, which secured exclusive development and commercialisation rights in China for mazdutide from Eli Lilly under undisclosed financial terms in 2019, is also approved in China to sell that drug as a treatment for type 2 diabetes.<\/p>\n
It is one of a number of Chinese weight loss and diabetes drugmakers ramping up competition with Novo and Lilly in the world\u2019s second-largest pharmaceutical market.
\nNovo sells injectable semaglutide for patients with type 2 diabetes in China under the brand name Ozempic to control blood sugar.<\/p>\n
In the trial, which enrolled 349 adults with type 2 diabetes and obesity, mazdutide showed greater improvements in both HbA1C \u2013 a measure of blood sugar over time \u2013 and weight reduction.<\/p>\n
Patients who took Innovent\u2019s drug at the 6 mg dose lost a mean of 10.29% of their weight from baseline compared to 6% with the 1 mg dose of injectable semaglutide. Innovent\u2019s drug also lowered patients\u2019 HbA1C by a mean of 2.03, compared to 1.84 for the 1 mg dose of injectable semaglutide.<\/p>\n
\u201cThe head-to-head DREAMS-3 study comparing mazdutide with semaglutide further showed that in patients with T2D and comorbid obesity mazdutide provides superior efficacy in both weight loss and glucose lowering,\u201d Innovent\u2019s chief R&D officer of general biomedicine, Lei Qian, said in a statement.<\/p>\n
A Novo Nordisk spokesperson did not immediately respond to a request for comment sent outside of normal business hours.<\/p>\n","protected":false},"excerpt":{"rendered":"
China\u2019s Innovent Biologics said on Monday its GLP-1 injection led to more weight loss and better control of blood sugar in patients with diabetes than injectable semaglutide, the active ingredient in Novo Nordisk\u2019s diabetes and weight-loss medicines. The late-stage head-to-head trial compared different doses of the two drugs in patients with diabetes and obesity to […]<\/p>\n","protected":false},"author":2,"featured_media":2351,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[36],"tags":[732],"class_list":{"0":"post-2350","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-sitefansalaran-international-news","8":"tag-chinas-innovent-says-its-glp-1-works-better-than-novos-semaglutide-in-diabetes-study"},"yoast_head":"\n